Feasibility study of the use of the TandemHeart® percutaneous ventricular assist device for treatment of cardiogenic shock

Catheterization and Cardiovascular Interventions

Volumn 68, Issue 2, 2006, Pages 211-217

  Burkhoff, Daniel ^a   O'Neill, William ^b   Brunckhorst, Corinna ^c   Letts, Dustin ^d   Lasorda, David ^e   Cohen, Howard A ^d,f  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

^f LENOX HILL HOSPITAL   (United States)

Author keywords

Cardiogenic shock; Left ventricular assist device; Myocardial infarction

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; CANNULATION; CARDIOGENIC SHOCK; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEART ASSIST DEVICE; HEART INDEX; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC MONITORING; HUMAN; INFECTION; LEG ISCHEMIA; LUNG CAPILLARY PRESSURE; MALE; MEAN ARTERIAL PRESSURE;

AGED; BLOOD PRESSURE; CARDIAC OUTPUT; FEASIBILITY STUDIES; FEMALE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PROSTHESIS DESIGN; PULMONARY WEDGE PRESSURE; SHOCK, CARDIOGENIC;

EID: 33746717522     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20796     Document Type: Article

References (23)

1. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
2. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996;28:1323-1327.
3. Packer M, Bristōw MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
4. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
5. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199.
6. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
7. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435-1443.
8. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
9. Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD, Hasdai D, Holmes DR, Bates ER, Topol EJ, Califf RM, Ohman EM. Lack of progress in cardiogenic shock: Lessons from the GUSTO trials. Eur Heart J 2000;21:1928-1936.
10. Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-1 trial experience. The GUSTO-1 Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 1995;26:668-674.
11. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999;340:1162-1168.
12. Anderson RD, Ohman EM, Holmes DR Jr, Col I, Stebbins AL, Bates ER, Stomel RJ, Granger CB, Topol EJ, Califf RM. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the GUSTO-1 Study. Global utilization of streptokinase and TPA for occluded coronary arteries. J Am Coll Cardiol 1997;30:708-715.
13. Ohman EM, Hochman JS. Aortic counterpulsation in acute myocardial infarction: Physiologically important but does the patient benefit? Am Heart J 2001;141:889-892.
14. Sanborn TA, Sleeper LA, Bates ER, Jacobs AK, Boland J, French JK, Dens J, Dzavik V, Palmeri ST, Webb JG, Goldberger M, Hochman JS. Impact of thrombolysis, intra-aortic balloon pump counter-pulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000;36:1123-1129.
15. Feneley MP, Chang VP, O'Rourke MF. Myocardial rupture after acute myocardial infarction. Ten year review. Br Heart J 1983;49:550-556.
16. Bolooki H. Emergency cardiac procedures in patients in cardiogenic shock due to complications of coronary artery disease. Circulation 1989;79:1137-1148.
17. Madsen JC, Daggett WM Jr. Repair of postinfarction ventricular septal defects. Semin Thorac Cardiovasc Surg 1998;10:117-127.
18. Davis N, Sistino JJ. Review of ventricular rupture: Key concepts and diagnostic tools for success. Perfusion 2002;17:63-67.
19. Nishimura RA, Schaff HV, Gersh BJ, Holmes DR Jr, Tajik AJ. Early repair of mechanical complications after acute myocardial infarction. JAMA 1986;256:47-50.
20. Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001;104:2917-2922.
21. Thiele H, Sick P, Boudriot E, Diederich K, Hambrecht R, Niebaur J, Schuler G. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2004;26:1276-1283.
22. Magovern JA, Sussman MJ, Goldstein AH, Szydlowski GW, Savage EB, Westaby S. Clinical results with the AB-180 left ventricular assist device. Ann Thorac Surg 2001;71 (Suppl 3):S121-S124; discussion S144-S146.
23. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003;107:2998-3002.